This article has been corrected: The ‘Antibodies and Compounds’ section has been updated to read, “The following antibodies were purchased from Cell Signaling Technology (Danvers, MA): anti-Smad2 and loading control antibodies (antiGAPDH or anti-beta actin).” In addition, the ‘Quantitative reverse transcription-PCR (qRT-PCR)’ section has been updated to read, “Primers for SERPINE, SMAD7, SNAI1, PLAUR, and MUC5AC were purchased….” The authors declare that these corrections do not change the results or conclusions of this paper.
Original article: Oncotarget. 2019; 10:810–824. 810-824. https://doi.org/10.18632/oncotarget.26574